We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biogen has so far netted just $300,000 from the sale of Aduhelm, its controversial antiamyloid antibody, a fraction of what the company anticipated for its recently approved Alzheimer’s treatment.